Loading clinical trials...
Loading clinical trials...
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Conditions
Interventions
Benralizumab 30 mg
Matched placebo
Locations
116
United States
Research Site
Huntington Beach, California, United States
Research Site
Grand Junction, Colorado, United States
Research Site
Gainesville, Florida, United States
Research Site
Louisville, Kentucky, United States
Research Site
White Marsh, Maryland, United States
Research Site
The Bronx, New York, United States
Start Date
November 25, 2019
Primary Completion Date
August 6, 2024
Completion Date
April 7, 2025
Last Updated
February 19, 2026
NCT07528820
NCT06930612
NCT05131958
NCT03401229
NCT03979716
NCT04532736
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions